GenVec, Inc.
(NASDAQ : GNVC)

( )
GNVC PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
-0.48%43.720.9%$906.73m
JNJJohnson & Johnson
1.96%136.570.6%$870.01m
MRKMerck & Co., Inc.
-0.41%70.930.6%$589.74m
LLYEli Lilly and Company
0.37%111.031.0%$519.32m
ABBVAbbVie, Inc.
3.05%91.902.2%$500.29m
BMYBristol-Myers Squibb Company
0.33%57.801.4%$347.60m
NVSNovartis AG Sponsored ADR
-1.17%84.760.2%$178.01m
AZNAstraZeneca PLC Sponsored ADR
0.15%39.141.3%$152.53m
GSKGlaxoSmithKline plc Sponsored ADR
-0.75%39.500.2%$88.09m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.74%43.060.1%$86.57m
SNYSanofi Sponsored ADR
-0.11%44.290.2%$59.05m
LCILannett Company, Inc.
2.17%4.2537.0%$7.26m
AKTXAkari Therapeutics Plc Sponsored ADR
-1.12%1.761.7%$0.15m

Company Profile

GenVec, Inc. is a clinical-stage gene delivery company, which engages in the development of therapeutics and vaccines. The firm designs, tests, and manufactures adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products include CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and is headquartered in Gaithersburg, MD.